Antibody evolution immunogens
US-2015366961-A1 · Dec 24, 2015 · US
CD40L vaccines, compositions, and methods related thereto
US9138472B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9138472-B2 |
| Application number | US-201113247484-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 28, 2011 |
| Priority date | Sep 28, 2010 |
| Publication date | Sep 22, 2015 |
| Grant date | Sep 22, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject.
First claim
Opening claim text (preview).
The invention claimed is: 1. A recombinant vector comprising genes sufficient to produce a viral like particle and a deoxyribonucleic acid sequence, wherein the deoxyribonucleic acid sequence transcribes into mRNA that encodes a lentiviral envelope protein followed by an internal ribosome entry site sequence operably linked to a sequence encoding CD40L. 2. The recombinant vector of claim 1 , wherein the lentiviral envelope protein is a HIV envelope protein.…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
- A61K39/21Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9138472B2 cover?
- The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject.
- Who is the assignee on this patent?
- Amara Rama Rao, Lai Lilin, Kwa Sue Fen, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/21. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).